1 Treating COVID

An abstract is unavailable.

Nearly 400 children between the ages of 12 and 17 were diagnosed with heart inflammation after receiving the ...

La Quinta Columna has revolutionized the scientific community with the official interim report of the analysis of the vaccination vial they released.

The Food and Drug Administration (FDA) said on Wednesday that it will add a warning of heart inflammation ...

mortality, in secondary outcomes, and in chemoprophylaxis, among people with, or at high risk of, COVID-19 infection. Data sources: We searched bibliographic databases up to April 25, 2021. Two review authors sifted for studies, extracted data, and assessed risk of bias. Meta-analyses were conducted and certainty of the evidence was assessed using the GRADE approach and additionally in trial sequential analyses for mortality. Twenty-four randomized controlled trials involving 3406 participants met review inclusion. Therapeutic Advances: Meta-analysis of 15 trials found that ivermectin reduced risk of death compared with no ivermectin (average risk ratio 0.38, 95% confidence interval 0.19–0.73; n = 2438; I2 = 49%; moderate-certainty evidence). This result was confirmed in a trial sequential analysis using the same DerSimonian–Laird method that underpinned the unadjusted analysis. This was also robust against a trial sequential analysis using the Biggerstaff–Tweedie method. Low-certainty evidence found that ivermectin prophylaxis reduced COVID-19 infection by an average 86% (95% confidence interval 79%–91%). Secondary outcomes provided less certain evidence. Low-certainty evidence suggested that there may be no benefit with ivermectin for “need for mechanical ventilation,” whereas effect estimates for “improvement” and “deterioration” clearly favored ivermectin use. Severe adverse events were rare among treatment trials and evidence of no difference was assessed as low certainty. Evidence on other secondary outcomes was very low certainty. Conclusions: Moderate-certainty evidence finds that large reductions in COVID-19 deaths are possible using ivermectin. Using ivermectin early in the clinical course may reduce numbers progressing to severe disease. The apparent safety and low cost suggest that ivermectin is likely to have a significant impact on the SARS-CoV-2 pandemic globally. Address for correspondence: Population Health Sciences Institute, Newcastle University, Baddiley-Clark Building, Richardson Road, Newcastle Upon Tyne NE2 4AX, United Kingdom. E-mail: andy.bryant@ncl.ac.uk The preprint of this review received no funding. This updated version was funded by the crowdfunding initiative https://www.gofundme.com/f/help-us-get-lifesaving-drug-approved-for-covid19 The authors have no conflicts of interest to declare. T. A. Lawrie and A. Bryant cowrote the review; they also sifted the search and classified studies for inclusion and entered and checked the data in RevMan and performed analyses. Data extraction was divided among T. A. Lawrie, A. Bryant, and T. Dowswell. T. Dowswell and A. Bryant graded the evidence. E. J. Fordham prepared the text on ivermectin mechanisms, use in pregnancy, and among the elderly. S. R. Hill prepared the brief economic commentary. Clinicians S. Mitchell and T. C. Tham contributed to the interpretation of the evidence in the discussion and conclusions. All authors reviewed and approved the final version of the manuscript. This article discusses off-label use of the FDA-approved medication ivermectin against COVID-19. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved....

Spike protein collects in ovaries and bone marrow according to Pfizer data from Japan. Clip from DarkHorse podcast. Full livestream CENSORED on YouTube Join us on Odysee https://odysee.com/@BretWeinstein:f https://odysee.com/@DarkHorsePodcastClips:b Full livestream here: Odysee for backup: https://odysee.com/@BretWeinstein:f/how-to-save-the-world,-in-three-easy:0 Dr. Robert Malone is the inventor of mRNA Vaccine technology. Mr. Steve Kirsch is a serial entrepreneur who has been researching adverse reactions to COVID vaccines. Bret talks to Robert and Steve about the pandemic, treatment and the COVID vaccines. Steve's paper on COVID vaccine reactions: https://trialsitenews.com/should-you-get-vaccinated/ Steve's Twitter: https://twitter.com/stkirsch COVID-19 Early Treatment Fund: https://www.treatearly.org/team/steve-kirsch Dr. Malone's website: https://www.rwmalonemd.com/mrna-vaccine-inventor Robert's LinkedIn profile: https://www.linkedin.com/in/rwmalonemd Robert's Twitter: https://twitter.com/RWMaloneMD Find Bret Weinstein on Twitter: @BretWeinstein, and on Patreon. https://www.patreon.com/bretweinstein https://twitter.com/BretWeinstein Please subscribe to this channel for more long form content like this, and subscribe to the clips channel @DarkHorse Podcast Clips for short clips of all our podcasts. DarkHorse merchandise now available at: store.darkhorsepodcast.org Theme Music: Thank you to Martin Molin of Wintergatan for providing us the rights to use their excellent music.

Spike protein is very dangerous, it's cytotoxic. Clip from DarkHorse podcast. Full livestream here: https://youtu.be/-_NNTVJzqtY Bitchute for backup: https://www.bitchute.com/video/TH2HAmTp40xq/ Dr. Robert Malone is the inventor of mRNA Vaccine technology. Mr. Steve Kirsch is a serial entrepreneur who has been researching adverse reactions to COVID vaccines. Bret talks to Robert and Steve about the pandemic, treatment and the COVID vaccines. Steve's paper on COVID vaccine reactions: https://trialsitenews.com/should-you-get-vaccinated/ Steve's Twitter: https://twitter.com/stkirsch COVID-19 Early Treatment Fund: https://www.treatearly.org/team/steve-kirsch Dr. Malone's website: https://www.rwmalonemd.com/mrna-vaccine-inventor Robert's LinkedIn profile: https://www.linkedin.com/in/rwmalonemd Robert's Twitter: https://twitter.com/RWMaloneMD Find Bret Weinstein on Twitter: @BretWeinstein, and on Patreon. https://www.patreon.com/bretweinstein https://twitter.com/BretWeinstein Please subscribe to this channel for more long form content like this, and subscribe to the clips channel @DarkHorse Podcast Clips for short clips of all our podcasts. DarkHorse merchandise now available at: store.darkhorsepodcast.org Theme Music: Thank you to Martin Molin of Wintergatan for providing us the rights to use their excellent music.

Ivermectin 12 MG is Used to Cure Viral care Infection. #Buy Ivermectin 12 Online and Get [ 12% OFF⭐ + Free Shipping ] World wide✈.

RNA virus infections can lead to the onset of severe diseases such as fever with haemorrhage, multiorgan failure, and mortality. The emergence and reemergence of RNA viruses continue to pose a significant public health threat worldwide with particular attention to the increasing incidence of flavivi …

Ivermectin Works For COVID-19 - LATEST STUDIES More lectures on drbeen.com Looking to support my educational work? Donate here: https://paypal.me/mobeensyed?locale.x=en_US Start your free trial - no credit card needed: https://members.drbeen.com/freetrial Original in-vitro study about Ivermectin https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7129059/ A study from bangladesh found that Ivermectin + Doxyclyclin significantly reduces mortality and morbidity in COVID-19 patients. https://clinicaltrials.gov/ct2/show/study/NCT04523831 A systemic review of the antiviral activity of Ivermectin https://www.nature.com/articles/s41429-020-0336-z https://journal.chestnet.org/article/S0012-3692(20)34898-4/fulltext PDF for the above study after it was accepted https://journal.chestnet.org/article/S0012-3692(20)34898-4/pdf Pre-print of the above study https://www.medrxiv.org/content/10.1101/2020.06.06.20124461v2 A search of various Ivermectin studies for your reading pleasure https://clinicaltrials.gov/ct2/results?cond=Covid19&term=ivermectin&cntry=&state=&city=&dist= Iota carrageenan and Ivermectin oral drops https://clinicaltrials.gov/ct2/show/results/NCT04425850?term=ivermectin&cond=Covid19&draw=2

Two small clusters of deaths after COVID-19 vaccination have been reported among nursing homes in Kentucky and Arkansas. ...

Background: Innovative approaches are needed to complement existing tools for malaria elimination. Ivermectin is a broad spectrum antiparasitic endectocide clinically used for onchocerciasis and lymphatic filariasis control at single doses of 150 to 200 mcg/kg. It also shortens the lifespan of mosquitoes that feed on individuals recently treated with ivermectin. However, the effect after a 150 to 200 mcg/kg oral dose is short-lived (6 to 11 days). Modeling suggests higher doses, which prolong the mosquitocidal effects, are needed to make a significant contribution to malaria elimination. Ivermectin has a wide therapeutic index and previous studies have shown doses up to 2000 mcg/kg (ie, 10 times the US Food and Drug Administration approved dose) are well tolerated and safe; the highest dose used for onchocerciasis is a single dose of 800 mcg/kg. Objective: The aim of this study is to determine the safety, tolerability, and efficacy of ivermectin doses of 0, 300, and 600 mcg/kg/day for 3 days, when provided with a standard 3-day course of the antimalarial dihydroartemisinin-piperaquine (DP), on mosquito survival. Methods: This is a double-blind, randomized, placebo-controlled, parallel-group, 3-arm, dose-finding trial in adults with uncomplicated malaria. Monte Carlo simulations based on pharmacokinetic modeling were performed to determine the optimum dosing regimens to be tested. Modeling showed that a 3-day regimen of 600 mcg/kg/day achieved similar median (5 to 95 percentiles) maximum drug concentrations (Cmax) of ivermectin to a single of dose of 800 mcg/kg, while increasing the median time above the lethal concentration 50% (LC50, 16 ng/mL) from 1.9 days (1.0 to 5.7) to 6.8 (3.8 to 13.4) days. The 300 mcg/kg/day dose was chosen at 50% of the higher dose to allow evaluation of the dose response. Mosquito survival will be assessed daily up to 28 days in laboratory-reared Anopheles gambiae s.s. populations fed on patients’ blood taken at days 0, 2 (Cmax), 7 (primary outcome), 10, 14, 21, and 28 after the start of treatment. Safety outcomes include QT-prolongation and mydriasis. The trial will be conducted in 6 health facilities in western Kenya and requires a sample size of 141 participants (47 per arm). Sub-studies include (1) rich pharmacokinetics and (2) direct skin versus membrane feeding assays. Results: Recruitment started July 20, 2015. Data collection was completed July 2, 2016. Unblinding and analysis will commence once the database has been completed, cleaned, and locked. Conclusions: High-dose ivermectin, if found to be safe and well tolerated, might offer a promising new tool for malaria elimination.

With COVID-19 vaccines on the precipice of mass distribution, the one thing the media isn't talking about is the definition of "effective" when it comes to these vaccines

Caly et al.1 reported that ivermectin inhibited severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) in vitro for up to 48 hours using ivermectin at 5 μM. The concentration resulting in 50% i...

People are dying, but what are they dying from? Is it an all-powerful virus that is doing hundreds of thousands of people in, or is it medical ignorance and medical malpractice? Ignorance is deadly in medicine and is usually sourced in arrogance and pharmaceutical greed and power, which is in full view with the American... View Article

Newly unearthed documents from Moderna Pharmaceuticals Covid patent application include a claim of concern about a "deliberate release of SARS coronavirus" 9 months before the official emergence of Covid-19. In addition, it turns out that Moderna may not have the legal right to even release its vaccine in the next few weeks because the company appears to be infringing on an exisiting patent for the core technology. Is this why Moderna's executives are selling their stock? Check out our sponsor ISE.Media ---------------- Support Truth in Media by visiting our sponsors: ISE.Media https://ISE.Media Pulse Cellular: Use code "TRUTH" for 10% every plan for life. https://truthinmedia.com/phone Pure VPN: Military grade vpn protection. https://truthinmedia.com/vpn Brave Browser: Open source and built by a team of privacy focused, performance oriented pioneers of the web. https://truthinmedia.com/brave #benswann